Wegovy is Novo Nordisk's branded semaglutide for chronic weight management. The injectable form launched in 2021. Oral Wegovy — a reformulated, higher-dose oral semaglutide — launched in late 2025 and early 2026, with the 1.5mg starter dose at $149/month and the 4mg dose moving from $149 to $199 effective April 15, 2026.
The most cited Wegovy data: SELECT (20% MACE reduction in non-diabetic adults with obesity), the STEP series for weight loss, and recent comparative work suggesting oral Wegovy may edge ahead of Foundayo (orforglipron) on weight loss despite Foundayo's HbA1c lead. Wegovy is on the FDA's April 30 proposal to exclude semaglutide from the 503B bulks list — the compounded-Wegovy market has been a core revenue threat for Novo.
Stories here cover pricing, head-to-head readouts, payer coverage, and the compounding economics.
On September 7, 2026, Novo Nordisk reported first Phase 3 STEP Young results in children aged 6 to under 12 with obesity — 40.4% below the obesity threshold at week 68 on semaglutide plus lifestyle modification versus 0% on placebo, with no new safety signal and no growth or puberty concerns in 165 children over 68 weeks. Wegovy is currently approved in the U.S. for adolescents 12 and older; a supplemental filing to extend to children under 12 has not been announced. Full STEP Young results will be presented at ObesityWeek 2026 (November 14-17, Washington DC).
Rice University assistant professor Erin Standen and colleagues at the Mayo Clinic (Sean Phelan) and UCLA (Janet Tomiyama) published in the International Journal of Obesity on May 5 a study finding that adults who lose weight via GLP-1 receptor agonists like Ozempic and Wegovy face more judgment than those who lose weight through diet and exercise — or who do not lose weight at all. The stigma framing centers on 'easy way out' perceptions and intensifies if the patient later regains weight. The work joins the broader social-context literature shaping the GLP-1 era — including the Ozempic Face plastic-surgery surge, GLP-1-related shame disclosures, and patient-reported drift away from disclosing medication use to friends and family.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
NPR ran a consumer-facing explainer May 6 of the Medicare GLP-1 Bridge demonstration that begins July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D beneficiaries can access Wegovy, Foundayo, and the Zepbound KwikPen formulation for a $50/month copay through the Bridge after meeting prior-authorization criteria. The piece consolidates a regulatory thread that has been jagged in mainstream coverage — the BALANCE pilot's collapse in late April when CVS pulled out, the Trump-administration extension of the Bridge to 2027, and the May 2026 confirmation that state Medicaid agencies can opt in. NPR's translation arrives in the same window as Novo's May 6 Q1 print and the Hims & Hers May 11 print, both of which are partly leveraged on Bridge eligibility expanding the addressable patient base.
Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.
Novo Nordisk announced April 28 that it will present 52 abstracts at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), including new data from the REDEFINE 1 trial of CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg): body composition and muscle strength, achievement of BMI/waist-to-height ratio targets, and cardiovascular risk reduction. Additional presentations will cover higher-dose Wegovy (semaglutide 7.2 mg), the Wegovy pill (oral semaglutide 25 mg) from OASIS 4 and ORION trials, and obesity treatment outcomes in women. The disclosure sets up a significant amylin/GLP-1 combination data event exactly as Zealand and Roche's amylin-only petrelintide moves into Phase 3.
The Trump administration on April 22 cancelled the five-year BALANCE Medicare model that would have had private insurers pay for Wegovy and Zepbound as a regular benefit, after CVS opted out citing a projected $1.4 billion cost over 10 years. Medicare will instead cover the drugs directly through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, with beneficiaries paying $50/month copays.
An April 22 NPR report citing GoodRx research found that 12 million people each lost insurance coverage for Wegovy and Zepbound between 2025 and 2026, while 88% of those still covered face restrictions like prior authorization or BMI 40+ requirements. About 60% of GLP-1 users now pay out of pocket — often hundreds of dollars monthly — reframing the affordability debate after the BALANCE model's cancellation.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.
Novo Nordisk's oral Wegovy 4mg dose increased from the introductory $149/month to $199/month effective April 15, as previously announced. The 1.5mg starter dose remains at $149/month, while maintenance doses (9mg, 25mg) stay at $299/month. The price increase applies to the NovoCare self-pay channel.
The FDA granted Apotex Corp. the first-ever tentative approval for a generic semaglutide injection equivalent to Ozempic/Wegovy. Actual market entry is blocked by Novo Nordisk patents until ~2032, but the milestone proves a complex peptide injectable can meet FDA generic equivalence standards.
Novo Nordisk received accelerated FDA approval for Wegovy HD, a higher-dose injectable semaglutide offering ~21% weight loss, with aggressive discount pricing to fight Lilly's market share gains.
Three months into its launch, oral Wegovy has driven explosive prescription demand, largely attracting new patients who avoided injections. Early data suggest the pill is expanding the obesity market rather than cannibalizing injectable users.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.